Latest Content

Experts discussed biomarker testing, novel cancer therapies, multidisciplinary care, and strategies to expand access.

Shahzad Mian, MD, explains dry eye disease symptoms, key risk factors, and practical management strategies like drops and warm compresses.

This eta-analysis shows sleep variability—not averages—signals psychosis risk, with stage-specific patterns to guide digital biomarkers and care.

Agentic AI can fix behavioral health referral overload by matching patients to the right providers and boosting follow-through, cutting early dropout.

A recent study found semaglutide more than doubled the likelihood of MASH resolution, but it did not significantly improve fibrosis.

A new review argues that bulevirtide is unlikely to succeed as a stand-alone treatment and calls for combination regimens that restore antiviral immunity.

A budget impact model projects that covering delgocitinib cream for moderate to severe CHE could save a hypothetical US health plan $87.8 million over 3 years.

Navista names Jeff Hunnicutt COO, bringing in a well-known oncology leader with experience in technology and innovation at the practice level.

Moving to a subQ formulation makes sense, if you want to be 100% convenient for patients and the centers that treat them, explains Xavier Leleu, MD, PhD.